(Nasdaq: SLNH) Profile
OUR NEW PROFILE IS: (NASDAQ: SLNH) THIS DATA CENTER JUGGERNAUT IS SOLVING RENEWABLE ENERGY’SBIGGEST PROBLEM ALL WHILE BENEFITING FROM THE RISE OF BITCOIN REVENUE IN THE THIRD QUARTER INCREASED BY 176% TO $5.8 MILLION COMPARED TO $2.1 MILLION IN THE SECOND QUARTER OF 2023 SOLUNA HARNESSES THE POWER OF COMPUTING TO ACCELERATE THE RENEWABLE ENERGY FUTURE SLNH COMPLETED […]
(Nasdaq: ANIX) Profile
OUR NEW PROFILE IS: (NASDAQ: ANIX) ANIX HAS TWO VACCINES AIMED TO PREVENT BREAST CANCER AND OVARIAN CANCER ANIX HAD $23 MILLION IN CASH AS OF JULY 2023 CHECK OUT THE INVESTOR PRESENTATION HERE ____________________ Hello Everyone, Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of […]
(Nasdaq: GDC) Profile
OUR NEW PROFILE IS: (NASDAQ: GDC) ____________________ GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK GDC HAS BEEN SEEING A LOT OF ACTIVITY OVER THE PAST 7 DAYS GD CULTURE GROUP UNVEILS ITS TRANSFORMATIVE AND PHOTOREALISTIC AI-DRIVEN DIGITAL HUMAN TECHNOLOGY ON TIKTOK GD CULTURE GROUP ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH PIER E […]
(NYSE American: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA. -THIS […]
(NASDAQ: SOPA) Profile
OUR NEW PROFILE IS: (NASDAQ: SOPA) WITH CASH ON HAND OF $8.2 MILLION (APPROXIMATELY $0.26 PER SHARE) AND BOOK VALUE OF $9.9 MILLION(APPROXIMATELY $0.32 PER SHARE) AS OF 30 SEPTEMBER 2023, SOPA IS WELL CAPITALISED FOR CONTINUING ACQUISITIONS OF SEA COMPANIES IN ITS DIGITAL ADVERTISING, TRAVEL, LIFESTYLE, TELECOMMUNICATIONS, AND LOYALTY/FINTECH VERTICALS FOR THE REST OF 2023 AND 2024 SOPA JUST ANNOUNCEED THAT […]
(Nasdaq: GDC) Profile
OUR NEW PROFILE IS: (NASDAQ: GDC) ____________________ GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK GDC HAS BEEN ON A SLOW AND STEADY MOVE NORTH THROUGHOUT 2023 __________________________________________ Hello Everyone, We have another profile for you to look at and research before the open on Monday morning. Pull up GDC. This is another […]
(Nasdaq: SXTP) Profile
OUR NEW PROFILE IS: (NASDAQ: SXTP) ____________________ SXTP HAS JUST 5 MILLION SHARES IN THE FLOAT ACCORDING TO FINVIZ SXTP PIVOTS TO REFOCUS ON COMMERCIALIZATION OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES READ THE INVESTOR PRESENTATION HERE __________________________________________ Hello Everyone, I hope that you are paying attention. We sent out our last profile at 2 pm […]
(Nasdaq: NNVC) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: NNVC) NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!!!! READ THE INVESTOR PRESENTATION HERE ______________________________________________________________ Hello Everyone, We have another new profile that we want you to research right away. This is one you should […]
(NYSE American: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA READ THE INVESTOR […]
(Nasdaq: IVP) Profile
OUR NEW PROFILE IS: (NASDAQ: IVP) ____________________ REVENUE RUN RATE ~$19M, 13LOCATIONS ACROSS 9 STATES, ~$3.5M IN REI 3 NEW LOCATIONS UNDER LOI WHICH WILL BRING AN ADDITION $6M OF ANNUAL REVENUE AND $2M IN REI IN THE LAST 2 MONTHS THE COMPANY HAS PROPOSED ACQUISITIONS TO ADD 3 NEW ANIMAL HOSPITALS TO THEIR CURRENT […]